Retailers could be in for a jolly jump in holiday sales despite headwinds like the U.S.-China trade war and threat of another economic slowdown.Retailread more
After a series of setbacks on the road to an initial public offering, the parent company of real estate start-up WeWork is delaying the move, sources told CNBC Monday.Technologyread more
Apple isn't trying to blow our minds with groundbreaking new features on the iPhone 11, but is making lots of little improvements each year, this year focusing on cameras and...Technologyread more
Saudi Arabia's defense spending is the world's third-largest — behind the U.S. and China, says Gary Grappo, former U.S. ambassador to Oman.Energyread more
Chinese officials are expected to be in Washington this week to hold consultations with the U.S. ahead of high-level trade talks in October.World Economyread more
The ballot comes at a precarious time for the country's longest serving prime minister, with the right-wing incumbent facing formidable challenges.World Politicsread more
Iran will never hold talks with America, the country's Supreme Leader Ayatollah Ali Khamenei said on state television Tuesday morning.Politicsread more
Energy stocks are on fire Monday. Five experts weigh in on what this could mean.Trading Nationread more
President Donald Trump said Monday he's in no rush to respond to a coordinated attack that hit Saudi Arabia's oil industry over the weekend.Marketsread more
The price of oil could go sharply higher, depending on the duration of the disruption at Saudi oil facilities and whether there is a military response.Powering the Futureread more
Energy stocks, one of the worst-performing sectors this year, spiked Monday after an attack on Saudi Arabia's heart of oil production Saturday sent oil prices soaring.Marketsread more
Josh Jennings, a medical doctor turned Wall Street analyst, told CNBC on Tuesday he can't see how Johnson & Johnson or any other health-care company can say opioids weren't dangerously addictive.
"I don't think anyone in the health-care community can honestly look in the mirror and say opioids weren't addictive and it wasn't known clearly," Jennings said. "As a resident in 1998 to 2002, in my intern year, I knew opioids were addictive."
"In emergency rooms, 40% of my patients were coming in seeking opioids," Jennings added. "It's one of the reasons I left clinical medicine, actually."
After completing a residency in the Harvard/Massachusetts General Hospital Medicine-Pediatrics program, Jennings practiced as an attending physician at Mass General in the mid-2000s. He's now a senior research analyst covering the medical device sector at the financial services firm Cowen.
Jennings spoke to "Squawk Box" about Monday's landmark opioid ruling against Johnson & Johnson, in which an Oklahoma judge ordered J&J pay a $572 million fine. It was the first ruling in the U.S. that holds a drugmaker accountable for the opioid epidemic.
The ruling, which J&J intends to appeal, said the company and subsidiary Janssen repeatedly downplayed the risks of addiction to opioids. J&J said the decision in the case is "flawed" and that the state "failed to present evidence that the company's products or actions caused a public nuisance in Oklahoma."
J&J said in court that its marketing and promotion of pain medications were "appropriate and responsible." The company provided testimony from doctors and current and former employees who said the company's marketing practices were appropriate.
"This could be a catalyst for some deeper settlement talks," Jennings said, though he's not expecting one.
However, Jennings said it's a "relative positive" for the drugmaker, since investors were expecting the fine to be up to $5 billion. Oklahoma had sought more than $17 billion.
Purdue Pharma — the privately held maker of OxyContin, which has faced much of the blame for the nationwide crisis — and Teva each reached a settlement with Oklahoma before the trial started. Neither company admitted to any wrongdoing.
— CNBC's Berkeley Lovelace Jr. contributed to this report.